Biotech · Private company
BreakBio Corp
Track this companyFree. Adds BreakBio Corp to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- BreakVaxPhase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
- BreakVaxPhase 2 · Triple-Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Ipilimumab 2.5 mgPhase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
- Ipilimumab 2.5 mgPhase 2 · Triple-Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Losartan and aspirinPhase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
- Losartan and aspirinPhase 2 · Triple-Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Triple-Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Standard-of-care chemotherapyPhase 2 · Triple-Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Temozolomide (TMZ)Phase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyPHASE1_PHASE2 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07762703 · fetched Nov 12, 2026
- Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyPHASE1_PHASE2 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07762716 · fetched Nov 12, 2026